The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists
Abstract
This article was published at Annals.org on 7 November 2023.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Surprisingly little research has been directed at a comprehensive assessment of even the most frequent GI adverse events.
“surprisingly little research has been directed at a comprehensive assessment of even the most frequent GI adverse events (125).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [125]
Citations
Cites
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Self-citationHalawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224
Acosta, A., Camilleri, M., Abu Dayyeh, B., Calderon, G., Gonzalez, D., McRae, A., Rossini, W., Singh, S., Burton, D., & Clark, M. M. (2021) · Obesity · doi:10.1002/oby.23120 · Cited by 222
Umapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193
Self-citationGastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management
Du, Y., Rayner, C. K., Jones, K. L., Talley, N. J., & Horowitz, M. (2018) · Diabetes Care · doi:10.2337/dc17-1536 · Cited by 182
Self-citationSemaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Jensterle, M., Ferjan, S., Ležaič, L., Sočan, A., Goričar, K., Zaletel, K., & Janez, A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14944 · Cited by 102
Jalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87
Self-citationJones, K. L., Huynh, L. Q., Hatzinikolas, S., Rigda, R. S., Phillips, L. K., Pham, H. T., Marathe, C. S., Wu, T., Malbert, C., Stevens, J. E., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13956 · Cited by 78
Self-citationTrahair, L. G., Nauck, M. A., Wu, T., Stevens, J. E., Buttfield, M., Hatzinikolas, S., Pham, H., Meier, J. J., Rayner, C. K., Horowitz, M., et al. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1784-6185 · Cited by 20
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 276
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“72 Although based primarily on anecdotal and case reports, concerns regarding risk of regurgitation and pulmonary aspiration due to delayed gastric emptying have resulted in guidance from the American Society of Anesthesiologists (ASA) Task Force on Preoperative Fasting for use of these medications…”
BackgroundClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
Self-citationMoiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
Rivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara-Breitinger, K. M., Gulati, M., & Bakris, G. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15529 · Cited by 59
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“Given the role of GLP-1RAs and other incretin-based medications widely used for the treatment of T2D and obesity, surprisingly little research has been directed at a comprehensive assessment of even the most frequent GI adverse events (125).”
Self-citationNoh, Y., Yin, H., Yu, O. H. Y., Bitton, A., & Azoulay, L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03420 · Cited by 15
Umpierrez, G. E., Pasquel, F. J., Duggan, E. W., & Galindo, R. J. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241231565 · Cited by 16
Kovoor, J. G., Rayner, C. K., Wu, T., Jalleh, R. J., Maddern, G. J., Horowitz, M., & Jones, K. L. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108793 · Cited by 11
Self-citationAlqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Jalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Self-citationJones, K. L., Marathe, C. S., Wu, T., Rayner, C. K., Nauck, M. A., & Horowitz, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15631 · Cited by 5
Self-citationSelf-reported side effects of semaglutide and tirzepatide in online communities
Sehgal, N. K. R., Tronieri, J. S., Ungar, L., & Guntuku, S. C. (2026) · Nature Health · doi:10.1038/s44360-026-00108-y · Cited by 7
Horowitz, M., Cai, L., & Islam, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.326 · Cited by 3
Self-citationCoutinho, S., Varghese, C., Buenz, E. J., Calder, S. S., Gharibans, A. A., O’Grady, G., Daker, C., Andrews, C. N., Calder, S. S., & Gharibans, A. A. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.07.027
Oral GLP-1 receptor agonists: competition for efficacy and tolerability
Nauck, M. A., & Horowitz, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00360-0
Self-citationOria, L., & Darkhabani, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71474
Metadata
- Authors
- Jalleh, R. J., Jones, K. L., Nauck, M., & Horowitz, M.
- Affiliations
- The University of Adelaide (AU)
- St. Josef-Hospital (DE)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2023-11
- Volume
- 176
- Issue
- 11
- Pages
- 1542-1543
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4388406346
- Cited by
- 18
- References
- 9
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- gastric emptying, gastrointestinal symptoms, GLP-1 receptor agonists, semaglutide, tirzepatide, type 2 diabetes, obesity, retatrutide, orforglipron, drug safety assessment, glycemic control
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Blood Glucose, Gastric Emptying, Glucagon, Humans, Insulin, Peptide Fragments
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
